Predilife S.A. (FRA:0GA)

Germany · Delayed Price · Currency is EUR

1.960

-0.320 (-14.04%)

At close: Jun 26, 2026

-44.79% (1Y)

Market Cap	9.11M -34.3%
Revenue (ttm)	728.08K +142.0%
Net Income	-3.80M
EPS	-1.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93
Open	2.290
Previous Close	2.280
Day's Range	1.960 - 2.290
52-Week Range	1.960 - 3.620
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 15, 2026

About Predilife

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2004

Employees 27

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 0GA

Financial Performance

In 2024, Predilife's revenue was 493,202, an increase of 55.20% compared to the previous year's 317,794. Losses were -4.26 million, 0.96% more than in 2023.

Financial Statements